The disclosure provides oral cysteamine and cystamine formulations useful for treating cystinosis and neurodegenerative diseases and disorders. The formulations provide controlled release compositions that improve quality of life and reduced side-effects.

The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.

A device for the treatment of periodontal disease includes a handle that has a configuration familiar to dental professionals, and a detachable tip or cartridge, that is locked into the handle when use. The device provides for automatically delivering a single dose of medicament, such as a powdered preparation of antibiotic, to a periodontal pocket for treatment of infection or disease.

The present invention discloses a composition for preparing a pain relieving drug, which includes poplar bark, Ligusticum wallichii, curcumin, ambergris, processed Radix Aconiti Lateralis, ray cartilage extract, wild ginseng, fructus psoraleae, garden balsam stem, pratt mountainash root-bark, annona muricata, Arisaema heterophyllum Blume, resina draconis, frankincense, myrrh, Brazilian sapodilla and camphor. The composition can be added with an appropriate auxiliary material to be made into dosage forms suitable for oral administration or external use, such as oral liquid, a patch, a liniment, a sustained-release agent and the like.

A microcapsule suspension for treating a protein-containing surface includes droplets of a dispersed water-immiscible core phase, an aqueous continuous phase, and a wall surrounding each core phase droplet. The wall includes the salt formed from at least one Lewis base reactant and at least one Lewis acid reactant, wherein at least one Lewis base reactant or Lewis acid reactant is amphiphilic and wherein at least one Lewis acid reactant is selected from the group consisting of proteins, protein hydrolysates, charged amino acids, and water-soluble salts of any of these.

Described herein are transdermal formulations of phytocannabinoids and methods of using the same in the treatment of pain and/or inflammation.

The disclosure relates, in general, to treatment of fatty liver disorders comprising administering compositions comprising cysteamine or cystamine compositions. The disclosure provides administration of enterically coated cysteamine compositions to treat fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

A plurality of heterogeneous microparticles can be provided, each having a shell, a payload, and a cap. The shell can define a core and an orifice in fluid communication with the core. The payload can be disposed within the core. The cap can be coupled to the shell so as to seal the orifice. The shell and cap of the microparticles can be formed by an additive manufacturing method, for example, by patterning of photomaterials using electromagnetic radiation or a particle beam. When subjected to a triggering event, at least a portion of each orifice can be exposed from the respective cap so as to release, through the exposed orifice portion, the corresponding payload from the core of the shell. The microparticles can be used in various applications, such as controlled delivery of drugs, chemicals, or biological agents, self-healing or self-lubricating materials, and failure prevention or mitigation.

The present invention is directed to micro and nanosized capsule compositions and methods of using and making the capsule compositions. The capsule compositions comprise an outer layer of lipids and/or polymers and inner contents comprising semiconductor nanoparticles. The nanoparticles are either metal oxides or quantum dots and will produce reactive oxygen species when irradiated with either electromagnetic radiation or ultrasound. The reactive oxygen species will degrade the outer layer of the capsule and cause the release of the contents, including the reactive oxygen species, into the local environment. The contents may optionally include cancer treating agent, water treating agents, antimicrobials, imaging and/or contracting agents. The outer layer may be further coated to protect it from environmental factors and/or be conjugated with a targeting molecule to increase delivery to a target.

A method of preventing progression of an appearance or effect of aging in a subject is provided. A method of preventing, limiting, or inhibiting injury to skin integrity in a subject is also provided. A method of substantially maintaining a state of skin integrity in a subject is further provided. A method of preventing a topographical change of a cutaneous layer of skin in a subject is still further provided. The methods comprise administering an effective amount of a preparation comprising ammonia oxidizing microorganisms to the subject. Related preparations and kits are also provided.